Mifepristone Paternalism at the FDA
-
Published:2023
Issue:3
Volume:51
Page:554-559
-
ISSN:1073-1105
-
Container-title:Journal of Law, Medicine & Ethics
-
language:en
-
Short-container-title:J. Law. Med. Ethics
Abstract
AbstractThis article explores the role of the Food and Drug Administration (FDA) in drug approval and restrictions to mifepristone access in the context of historical regulation and current litigation.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects